Remedy Meds vs Hers: GLP-1 Telehealth Comparison

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Remedy Meds and Hers are both telehealth platforms offering GLP-1 medications for weight management, but their operating models differ significantly. Remedy Meds functions primarily as a prescription-fulfillment service, while Hers positions itself as a women-focused health platform. Understanding their distinct approaches helps patients identify which framework aligns with their clinical needs and preferences.

Why does this matter? Remedy Meds vs Hers represents a broader shift toward accessible, direct-to-consumer GLP-1 pathways. However, each platform operates under different regulatory and clinical oversight models. PlexusDx offers a precision-wellness alternative using 503A compounded medications paired with optional genetic-pathway assessment, enabling more tailored clinical conversations with licensed providers.

Remedy Meds: Operational Model and Clinical Framework

Remedy Meds operates as a prescription-based telehealth service connecting patients with licensed providers for GLP-1 evaluation and ongoing monitoring. The platform emphasizes rapid assessment and medication dispatch, targeting patients seeking efficient access to compounded semaglutide and tirzepatide formulations.

Clinical oversight at Remedy Meds includes provider consultation, baseline eligibility screening, and periodic follow-up appointments. Medication pricing typically ranges from $149/mo monthly depending on compound type and dose. The platform integrates prescription fulfillment with basic clinical management, though genetic or biomarker-based personalization is not part of their standard workflow.

Hers Platform: Women-Centered Health and GLP-1 Access

Hers is a subscription-based women's health platform that includes GLP-1 medications alongside contraception, hormone therapy, and dermatology services. The platform emphasizes community support, educational content, and integrated care—marketing itself as a one-stop telehealth destination for female patients.

Hers offers branded and compounded GLP-1 options with monthly pricing and subscription flexibility. Clinical consultation is required, but the platform prioritizes affordability bundling and member perks. Hers does not routinely integrate genetic testing or peptide-pathway assessment into their standard clinical protocols.

Comparative Framework: Remedy Meds vs Hers vs Compounded Alternatives

All three pathways—Remedy Meds, Hers, and compounded-focused providers—deliver licensed prescriptions and clinical oversight. Key differences emerge in operational focus, pricing transparency, genetic integration, and personalization depth. The table below outlines clinical and operational distinctions.

Factor	Remedy Meds	Hers	PlexusDx Compounded Model
Primary Focus	GLP-1 prescription efficiency	Multi-service women's health	Precision-guided compounding + genetics
Genetic Testing	Not offered	Not offered	Precision Peptide Genetic Test (optional)
Compounding Source	Licensed 503A pharmacy	Branded or 503A compounding	Verified 503A compounding only
Medication Range	Semaglutide, tirzepatide	Semaglutide, tirzepatide, branded options	Semaglutide, tirzepatide, oral formulations
Monthly Cost Range	$149/mo	$99–$299 (varies by service bundle)	$129-$369/mo (based on compound and dose)
Provider Consultation Model	Telehealth visit required	Telehealth visit required	Licensed provider consultation + optional genetic review
Follow-up Monitoring	Standard clinical follow-ups	Community + clinical support	Clinical + genetic-pathway context support

Clinical Personalization: Beyond Standard Enrollment

Standard telehealth enrollment typically involves BMI assessment, medical history review, and basic lab work. However, GLP-1 response variability is significant—some patients achieve rapid weight loss, while others respond more gradually or experience dose-limiting side effects. Individual genetics influence peptide-pathway sensitivity and medication efficacy.

Remedy Meds and Hers focus on accessible, rapid-turnaround enrollment. PlexusDx adds optional genetic-pathway assessment via the Precision Peptide Genetic Test, which examines variants in GLP1R, GIPR, FTO, and MC4R genes. This may help provide context for clinical conversations about expected response patterns, though genetic predisposition does not guarantee exact medication outcomes.

Who Remedy Meds vs Hers Serves—And When Genetic Context Matters

Remedy Meds attracts patients seeking streamlined, prescription-focused GLP-1 access with minimal ancillary services. Hers appeals to women seeking integrated health management alongside weight-loss medication. Both serve patients who value rapid onboarding and straightforward pricing.

Patients who have had mixed or unclear GLP-1 responses in the past, or who want biomarker context before starting treatment, may benefit from PlexusDx's genetic-pathway option. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) should be interpreted with a qualified healthcare provider to inform dosing strategy and expectation-setting.

Safety Monitoring and Regulatory Oversight

All three models operate under licensed provider supervision and medication dispensing laws. Remedy Meds, Hers, and PlexusDx all source from licensed pharmacies. Compounded medications (via 503A pharmacies) are not FDA-approved but operate under section 503A compounding authority and state pharmacy regulation.

Side effects—nausea, constipation, fatigue—are common with GLP-1 therapy and require ongoing monitoring. Telehealth platforms provide periodic check-ins; in-person care may be necessary for complications. PlexusDx supports clinical decision-making with genetic-pathway context, but serious adverse events require immediate provider contact regardless of platform.

How PlexusDx Supports a More Personalized Approach

PlexusDx differentiates its approach by integrating optional genetic-pathway assessment into the clinical conversation. The Precision Peptide Genetic Test examines key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that influence peptide-pathway sensitivity. This context may help providers tailor dosing, frequency, and formulation choice more precisely than standard enrollment alone.

The Precision Peptide Genetic Test reveals predispositions in peptide genetic pathways—not exact medication response or pharmacogenetic liability. Results should be interpreted alongside clinical presentation, medical history, and provider expertise. A test result does not predict whether a patient will lose weight or tolerate a specific medication.

When considering Remedy Meds vs Hers, patients interested in deeper clinical personalization should ask their provider about genetic-pathway assessment. PlexusDx offers this as an optional add-on ($99) or standalone test ($298), supporting a more informed provider conversation about expected response variability and individualized treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Remedy Meds and Hers?

Remedy Meds is a prescription-focused telehealth service emphasizing rapid GLP-1 access. Hers is a multi-service women's health platform offering GLP-1 alongside contraception and dermatology. Both require provider consultation; Hers emphasizes bundled services and community features.

Does Remedy Meds or Hers use genetic testing to personalize GLP-1 treatment?

No. Remedy Meds and Hers do not offer genetic-pathway testing as standard practice. PlexusDx provides optional Precision Peptide Genetic Testing to support clinical conversations about individual peptide-pathway predispositions, interpreted with your provider.

Which platform offers compounded GLP-1 medications?

Remedy Meds and Hers both source from compounding pharmacies for cost-effective options. PlexusDx exclusively partners with licensed 503A compounding pharmacies, offering semaglutide ($149/mo), tirzepatide ($249/mo), oral formulations, and combination protocols.

Are compounded GLP-1 medications safe?

Compounded GLP-1 medications operate under FDA section 503A oversight and state pharmacy regulation. They are not FDA-approved but are legal and clinically monitored. Side effects and safety profiles are similar to branded versions. Provider supervision is required for all options.

How does genetic testing help with GLP-1 treatment planning?

The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that may influence peptide-pathway sensitivity. Results provide context for expected response patterns and can support provider discussions about dosing and formulation, though genetics do not guarantee outcomes.

What does PlexusDx offer that Remedy Meds and Hers don't?

PlexusDx integrates optional genetic-pathway assessment with 503A compounded medications and provides precision-wellness framing. The Precision Peptide Genetic Test supports individualized clinical conversations; standard telehealth enrollment typically omits this genetic-context layer.

Remedy Meds vs Hers: GLP-1 Telehealth Models Explained